Changes to methadone clearance during pregnancy

European Journal of Clinical Pharmacology

Volumn 61, Issue 10, 2005, Pages 763-768

  Wolff, Kim ^a   Boys, Annabel ^a   Rostami Hodjegan, Amin ^b   Hay, Alastair ^c   Raistrick, Duncan ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Leeds Addiction Unit   (United Kingdom)

Author keywords

Clearance; Methadone; Pharmacokinetic; Pregnancy

Indexed keywords

METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONGITUDINAL STUDY; LOW BIRTH WEIGHT; MALE; NEWBORN; OPIATE ADDICTION; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; METABOLIC CLEARANCE RATE; METHADONE; NARCOTICS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 27944474395     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0035-5     Document Type: Article

References (51)

1. Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H (2001) Psychiatric morbidity among adults living in private households, 2000. Office for National Statistics. The Stationary Office, London
2. Ellwood DA, Sutherland P, Kent C, O'Connor M (1987) Maternal narcotic addiction: pregnancy outcome in patients managed by a specialized drug-dependency antenatal clinic. Aust N Z Obstet Gynaecol 27:92-98
3. Finnegan LP (1983) Clinical perinatal and development effects of methadone. In: Cooper JR, Altman F, Brown BS, Czechowicz D (eds) Research on the treatment of narcotic addiction: state of the art. National Institute on Drug Abuse, Maryland, USA
4. Finnegan LP (1991) Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 23:191-201
5. Salerno LJ (1979) Prenatal care. In: Rementeria J (ed) Drug abuse in pregnancy and neonatal effects. CV Mosby, St. Louis, MO, USA, pp 19-29
6. Giles W, Patterson T, Sanders F, Batey R, Thomas D, Collins J (1989) Outpatient methadone programme for pregnant heroin using women. Aust N Z Obstet Gynaecol 29:225-229
7. Householder J, Hatcher R, Burns W, Chasnoff I (1982) Infants born to narcotic-addicted mothers. Psychol Bull 92:453-468
8. Finnegan LP (1980) (ed) Drug dependence in pregnancy: clinical management of mother and child. Castle House, London
9. Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, Langer M, Aschaver HN (2000) Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95:239-244
10. Suffet F, Brotman RA (1984) Comprehensive care program for pregnant addicts: obstetrical, neonatal, and child development outcomes. Int J Addict 19:199-219
11. Wilson GS (1989) Clinical studies of infants and children exposed prenatally to heroin. Ann N Y Acad Sci 562:183-194
12. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL (1985) Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 233:1-6
13. Mackie-Ramos RL, Rice JM (1988) Group psychotherapy with methadone-maintained pregnant women. J Subst Abuse Treat 5:151-161
14. Edelin KC, Gurganious L, Golar K, Oellerich D, Kyei-Aboagye K, Hamid M (1988) Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 71:399-404
15. Offidani C, Chiarotti M, De Giovanni N, Falasconi AM (1986) Methadone in pregnancy: clinical-toxicological aspects. J Toxicol Clin Toxicol 24:295-303
16. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH (1999) Alterations in methadone metabolism during late pregnancy. J Addict Dis 18:51-61
17. Department of Health (1999) Drug misuse and dependence-guidelines on clinical management. The Stationery Office, London
18. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G (2000) Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 95:1771-1783
19. Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193
20. Kharasch ED, Hoffer C, Whittington D, Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269
21. Lewis DFV, Ioannides C, Parke DV, Schulte-Hermann R (2000) Quantitative structure activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis. J Steroid Biochem Mol Biol 74:179-185
22. Tracy TS, Venkataramanan R, Glover DD, Caritis SN (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 192:633-639
23. Wadelius M, Darj E, Frenne G, Rane A (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62:400-407
24. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL (2005) Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 69:187-197
25. Clarke K, Formby J (2000) Feeling good, doing fine. Druglink 15:10-13
26. Blinick G, Jerez E, Walach RC (1973) Methadone maintenance, pregnancy and progeny. JAMA 225:477-479
27. Wolff K, Rostami-Hodjegan A, Shires S, Hay AW, Feely M, Calvert R, Raistrick D, Tucker GT (1997) The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 44:325-334
28. Rostami-Hodjegan A, Wolff K, Hay AW, Raistrick D, Calvert R, Tucker GT (1999) Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 48:43-52
29. Swift RM, Dudley M, DePetrillo P, Camara P, Griffiths W (1989) Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1:453-460
30. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N, Ohmori S, Igarashi T, Kitada M (2003) Direct interaction between substrates and endogenous steroids in the active site may change activity of cytochrome P450 3A4. Biochemistry 42:15068-15077
31. Sarkar M, Vadlamuri V, Ghosh S, Glover DD (2003) Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos 31:1-6
32. Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW (2004) Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther 311:728-735
33. Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systematic clearance pathways in infants. Clin Pharmacol 41:959-998
34. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL Hankins GD, Ahmed MS (2004) Methadone metabolism in the human placenta. Biochem Pharmacol 68:583-591
35. Matsunaga T, Maruyama M, Harada E, Katsuyama Y, Sugihara N, Ise H, Negishi N, Ikeda U, Ohmori S (2004) Expression and induction of CYP3As in human fetal hepatocytes. Biochem Biophy Res Commn 318:428-434
36. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891
37. Ring JA, Ghabrial H, Ching MS, Smallwood RA, Morgan DJ (1999) Fetal hepatic drug elimination. Pharmacol Ther 84:429-445
38. Finnegan LP, Kaltenbach K (1992) Neonatal abstinence syndrome. In: Hoekeman RA, Friedman SB, Nelson N, Seidel HM (eds) Primary pediatric care, 2nd edn. CV Mosby, St. Louis, MO, USA, pp 1367-1378
39. Levy M, Spino M (1993) Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy 13:202-211
40. Kandall SR (1995) Treatment options for drug-exposed infants. NIDA Res Monogr 149:58-77
41. Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM (1981) Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 29:211-217
42. Keller F, Griesshammer M, Haussler U, Paulus W, Schwarz A (2001) Pregnancy and renal failure: the case for application of dosage guidelines. Drugs 61:1901-1920
43. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J, ACTG 401 Study Team (2001) Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 27:153-160
44. Foster DJ, Somogyi AA, White JM, Bochner F (2004) Population pharmacokinetics of R-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57:742-755
45. Boulton DW, Arnaud P, Devane CL (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70:48-57
46. Rodrigo M, Ortega I, Soengas I, Lean N, Saurez E, Calvo R, Lukas JC (2004) Alpha-1-acid glycoprotein directly effects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding. J Pharm Sci 93:2836-2850
47. Department of Health (1993) Challenging childbirth: good practice in maternity care. The Stationery Office, London
48. Standing Conference on Drug Abuse (SCODA), Local Government Drugs Forum (1997) Drug using parents: policy guidelines for inter-agency working. LGDF, London
49. Mounteney J (1999) Drugs, pregnancy & childcare: a guide for professionals. ISDD, London
50. Nanovskaya TN, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS (2005) Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 69:583-591
51. Strolin Benedetti M, Baltes EL (2003) Drug metabolism and disposition in children. Fundam Clin Pharmacol 17:281-299